Revvity RVTY Diagnostics — Segment operating income

Similar metrics at other companies

ADiagnostics and Genomics — Operating Income (Loss)

$94M-6.9%

LHDiagnostics — Percent of Revenue Contributed

78%0.0pp

LHDiagnostics — Operating Income

$458.7M+7.3%

ALife Sciences and Diagnostics Markets — Income from operations

$161M+24.8%

LHDiagnostics — Revenue

$2.76B+5.0%

DGXDIS business — Operating Income (Loss)

$457M+10.4%

Questions, answered.

What is Revvity's diagnostics — segment operating income?

Revvity (RVTY) reported diagnostics — segment operating income of $76.12M in Q1 2026.

How has Revvity's diagnostics — segment operating income changed year-over-year?

Revvity's diagnostics — segment operating income increased by 2.8% year-over-year, from $74.02M to $76.12M.

What is the long-term trend for Revvity's diagnostics — segment operating income?

Over 3 years (2022 to 2025), Revvity's diagnostics — segment operating income has grown at a -23.9% compound annual growth rate (CAGR), from $781.17M to $344.17M.

What does diagnostics — segment operating income mean?

The profit earned from the diagnostics segment's core business operations.

How do you interpret diagnostics — segment operating income?

An increase indicates improved operational efficiency or higher margins, while a decrease signals rising costs or declining pricing power.

How does diagnostics — segment operating income compare across companies?

The primary benchmark for comparing the operational performance of business units across diversified companies.